ATE405266T1 - Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa - Google Patents

Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa

Info

Publication number
ATE405266T1
ATE405266T1 AT01274110T AT01274110T ATE405266T1 AT E405266 T1 ATE405266 T1 AT E405266T1 AT 01274110 T AT01274110 T AT 01274110T AT 01274110 T AT01274110 T AT 01274110T AT E405266 T1 ATE405266 T1 AT E405266T1
Authority
AT
Austria
Prior art keywords
heterocycles
inhibitors
factor
monocyclic
carbocycles
Prior art date
Application number
AT01274110T
Other languages
English (en)
Inventor
Irina Jacobson
Ruth Wexler
Jennifer Qiao
Suanne Nakajima
Mimi Quan
Shuaige Wang
Joanne Smallheer
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE405266T1 publication Critical patent/ATE405266T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
AT01274110T 2000-11-06 2001-10-30 Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa ATE405266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24610700P 2000-11-06 2000-11-06
US31355201P 2001-08-20 2001-08-20

Publications (1)

Publication Number Publication Date
ATE405266T1 true ATE405266T1 (de) 2008-09-15

Family

ID=26937728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274110T ATE405266T1 (de) 2000-11-06 2001-10-30 Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa

Country Status (9)

Country Link
US (2) US6710058B2 (de)
EP (1) EP1337251B1 (de)
JP (1) JP2004536084A (de)
AT (1) ATE405266T1 (de)
CA (1) CA2429113A1 (de)
DE (1) DE60135485D1 (de)
ES (1) ES2310540T3 (de)
HU (1) HUP0401832A2 (de)
WO (1) WO2002102380A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
PL370636A1 (en) * 2001-11-22 2005-05-30 Ono Pharmaceultical Co, Ltd. Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
WO2004101529A1 (ja) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314299D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
WO2004110997A1 (en) * 2003-06-19 2004-12-23 Glaxo Group Limited 3- sulfonylamino- pyrrolidine- 2- one derivatives as inhibitors of factor xa
AU2004257289A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US8710232B2 (en) * 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
CA2566094A1 (en) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
ES2375995T3 (es) * 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
JPWO2006104280A1 (ja) * 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
CN101309916A (zh) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 制备肉桂酰胺衍生物的方法
EP1953151A4 (de) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd Salze aus einer cynnamidverbindung oder solvate daraus
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AU2007252644A1 (en) * 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Heterocyclic type cinnamide derivative
WO2007135969A1 (ja) * 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. ウレア系－シンナミド誘導体
CL2008000582A1 (es) * 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
WO2008140111A1 (ja) * 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. シンナミド誘導体のワンポット製造方法
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CA2694401C (en) * 2007-08-31 2012-12-04 Eisai R&D Management Co., Ltd. Polycyclic compound
WO2009096349A1 (ja) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. 結晶性のシンナミド化合物またはその塩
WO2009119528A1 (ja) * 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
DE102008035552A1 (de) * 2008-07-30 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Substituierte Pyridine und ihre Verwendung
EP2623491A3 (de) 2009-04-02 2014-07-30 Merck Patent GmbH Piperidin- und piperazinderivate als autotaxininhibitoren
CN102369195B (zh) 2009-04-02 2014-04-16 默克专利有限公司 自分泌运动因子抑制剂
IN2012DN00602A (de) 2009-06-25 2015-06-12 Inst Univ De Ciencia I Technologia S A
ES2354550B1 (es) 2009-06-26 2011-11-15 Institut Univ. De Ciència I Tecnologia, S.A. Biblioteca de n-(1-fenil-2-oxo-3-piperidil)sulfonamidas para el descubrimiento de fármacos.
RU2012154308A (ru) 2010-05-17 2014-06-27 Эррэй Биофарма Инк. Пиперидинил-замещенные лактамы как модуляторы gpr119
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
TWI447141B (zh) * 2010-08-04 2014-08-01 Apaq Technology Co Ltd 導電聚合物及其裝置
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
KR20130130737A (ko) 2010-11-11 2013-12-02 사노피 ３­（６­아미노­피리딘­３일）­２­아크릴산 유도체의 제조방법
EP3323820B1 (de) 2011-02-28 2023-05-10 Epizyme, Inc. Substituierte 6,5-kondensierte bicyclische heteroarylverbindungen
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
WO2013010092A1 (en) 2011-07-13 2013-01-17 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
MX2014000536A (es) * 2011-07-13 2014-12-05 Novartis Ag Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
EP2734530A1 (de) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
IL296199B2 (en) 2012-04-13 2024-12-01 Eisai R&D Man Co Ltd Salt form of a human hi stone methyltransf erase ezh2 inhibitor
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014109987A1 (en) * 2013-01-09 2014-07-17 The Regents Of The University Of Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
AU2014337300B2 (en) 2013-10-16 2019-01-03 Eisai R&D Management Co., Ltd. Hydrochloride salt form for EZH2 inhibition
US20170217941A1 (en) * 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
EA039417B1 (ru) 2017-08-07 2022-01-25 Родин Терапеутикс, Инк. Бициклические ингибиторы гистондеацетилазы
EP3586847A1 (de) 2018-06-29 2020-01-01 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Verbindungen zur verwendung bei der vorbeugung oder behandlung von krebs
EP3587416A1 (de) * 2018-06-29 2020-01-01 Institut Univ. de Ciència i Tecnologia, S.A. 2-oxopiperidin-3-yl-derivate und verwendung davon
CN109020874B (zh) * 2018-09-04 2021-09-24 上海雅本化学有限公司 一种阿哌沙班中间体及其制备方法
EP3886854A4 (de) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung
CA3244064A1 (en) * 2021-12-23 2023-06-29 Vib Vzw TETRAHYDROBENZOAZEPINONES AND ASSOCIATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
EP4356909A1 (de) 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1(sulfonyl)-n-phenylpyrrolidin-2-carboxamid-derivate und ihre verwendung

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032602A (en) 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
EP0454444A1 (de) 1990-04-24 1991-10-30 Nissan Chemical Industries Ltd. Glutarimidderivate und Herbizide
GB9026389D0 (en) 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
DE69219354T2 (de) 1991-05-10 1997-10-23 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
CA2176043A1 (en) 1993-11-19 1995-05-26 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
AU720616B2 (en) 1996-02-22 2000-06-08 Merck & Co., Inc. Pyridinone thrombin inhibitors
AU715603B2 (en) 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2252964A1 (en) 1996-04-23 1997-10-30 Merck & Co., Inc. Pyrazinone thrombin inhibitors
AU4172397A (en) 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
CA2277929A1 (en) 1997-01-22 1998-07-23 Merck & Co., Inc. Thrombin inhibitors
UA57081C2 (uk) 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
EP0908764B1 (de) 1997-10-06 2002-03-27 Agfa-Gevaert Verfahren zur Verarbeitung eines photographischen Schwarzweiss-Silberhalogenidmaterials
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
AU1627799A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Parallel solution phase synthesis of lactams
EP1040108B1 (de) 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivate als antikoagulantien
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
EP1156803A4 (de) 1999-02-09 2004-03-17 Bristol Myers Squibb Co LACTAM INHIBITOREN DES FXa UND METHODE
IL146245A0 (en) 1999-05-19 2002-07-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
EA005367B1 (ru) 1999-05-19 2005-02-24 Фармация Корпорейшн Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения
WO2000069833A1 (en) 1999-05-19 2000-11-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
NZ514874A (en) 1999-05-19 2004-11-26 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors

Also Published As

Publication number Publication date
US20020183324A1 (en) 2002-12-05
US6951872B2 (en) 2005-10-04
HUP0401832A2 (hu) 2004-12-28
WO2002102380A1 (en) 2002-12-27
ES2310540T3 (es) 2009-01-16
CA2429113A1 (en) 2002-12-27
EP1337251A1 (de) 2003-08-27
US20040132718A1 (en) 2004-07-08
JP2004536084A (ja) 2004-12-02
EP1337251B1 (de) 2008-08-20
US6710058B2 (en) 2004-03-23
DE60135485D1 (de) 2008-10-02

Similar Documents

Publication Publication Date Title
ATE405266T1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
ATE241621T1 (de) Arylsulfonyle als faktor xa inhibitoren
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE266636T1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
ATE302775T1 (de) Carbolinderivate
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
ATE346067T1 (de) Carbolinderivate
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE477256T1 (de) Thienylverbindungen
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
DE60321810D1 (de) Neue tricyclische derivate als ltd4 antagonisten
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
EA200601176A1 (ru) 3-цианохинолиновые производные с антипролиферативной активностью
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE391715T1 (de) Heterozyklische mutilinester und deren verwendung als bakterizide
SE9902267D0 (sv) New compounds
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE60122559D1 (de) Indolderivate als pde5-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties